Sangamo Therapeutics
Translating ground-breaking science into genomic therapies.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| N/A | €0.0 | round | |
| investor | €0.0 | round | |
* | N/A | $146m | Post IPO Equity |
| Total Funding | 000k | ||
| USD | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 | 2027 |
|---|---|---|---|---|---|---|---|
| Revenues | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % growth | (6 %) | 1 % | 58 % | (67 %) | (8 %) | (15 %) | 147 % |
| EBITDA | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % EBITDA margin | (166 %) | (181 %) | 33 % | (145 %) | (67 %) | (194 %) | (11 %) |
| Profit | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| % profit margin | (161 %) | (173 %) | (146 %) | (169 %) | (163 %) | (218 %) | (49 %) |
| EV | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| EV / revenue | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| EV / EBITDA | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x | 00.0x |
| R&D budget | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 | 0000 |
| R&D % of revenue | 209 % | 225 % | 133 % | 193 % | - | - | - |
Source: Company filings or news article, Equity research estimates
Related Content
Sangamo Therapeutics, Inc. is a biotechnology company focused on developing genetic cures for severe diseases. The company leverages its proprietary zinc finger technology, a method for editing genes, to create treatments that go beyond merely managing symptoms. Sangamo operates in the gene-based therapeutics market, which includes gene therapy, gene editing, cell therapy, and gene regulation.
The company primarily serves patients suffering from severe genetic disorders, such as Hemophilia A, Fabry disease, and Sickle Cell Disease. These are conditions where traditional medicine often falls short, offering only symptom management rather than a cure. Sangamo's innovative approach aims to provide long-term solutions by addressing the root causes of these diseases at the genetic level.
Sangamo's business model revolves around research and development (R&D) and strategic partnerships. The company invests heavily in R&D to advance its proprietary technologies and bring new therapies to market. Additionally, Sangamo collaborates with major pharmaceutical companies like Pfizer to co-develop treatments, which helps to share the financial burden and accelerate the development process.
Revenue for Sangamo comes from multiple streams. The company earns money through research grants, milestone payments, and royalties from its partnerships. For instance, successful clinical trials and the eventual commercialization of therapies developed in collaboration with partners like Pfizer can result in significant financial returns.
In summary, Sangamo Therapeutics is a pioneering biotech firm dedicated to developing genetic cures for severe diseases. It operates in the gene-based therapeutics market, serving patients with conditions that traditional medicine struggles to treat effectively. The company makes money through R&D investments, strategic partnerships, and various revenue streams including grants, milestone payments, and royalties.
Keywords: biotechnology, gene therapy, gene editing, cell therapy, genetic cures, zinc finger technology, Hemophilia A, Fabry disease, Sickle Cell Disease, R&D.
